Sagimet Biosciences Inc. (SGMT)
NASDAQ: SGMT · Real-Time Price · USD
6.56
+0.33 (5.30%)
Feb 3, 2026, 4:00 PM EST - Market closed
Sagimet Biosciences Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
14
Market Cap
213.34M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 2.00M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Arcturus Therapeutics Holdings | 97.60M |
| Alector | 69.05M |
| Protalix BioTherapeutics | 61.84M |
| Voyager Therapeutics | 31.32M |
| Silence Therapeutics | 25.83M |
| Tonix Pharmaceuticals Holding | 10.30M |
| Orchestra BioMed Holdings | 2.82M |
| Inhibikase Therapeutics | 1.00 |
SGMT News
- 1 day ago - Sagimet Announces Positive 52-Week Data from License Partner Ascletis' Open-Label Phase 3 Clinical Trial Evaluating the Long-Term Safety of ASC40 (Denifanstat) Tablets in Patients with Moderate to Severe Acne - GlobeNewsWire
- 5 days ago - Ascletis Announces Positive Topline Results from Its Phase III Open-Label Study of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne - PRNewsWire
- 8 days ago - Biotech Veteran and Virologist Joins CancerVax as Senior Scientific Advisor - GlobeNewsWire
- 26 days ago - Sagimet Biosciences Announces Poster Presentation at the 10th Annual MASH-TAG 2026 Conference - GlobeNewsWire
- 6 weeks ago - Sagimet: Positive Denifanstat Combination PK Data Could Lead To Untapped Market - Seeking Alpha
- 6 weeks ago - Sagimet Biosciences Announces Positive Results from the Phase 1 PK Clinical Trial of Denifanstat and Resmetirom Combination - GlobeNewsWire
- 7 weeks ago - Sagimet's License Partner Ascletis Announced Acceptance of New Drug Application for Denifanstat for the Treatment of Moderate to Severe Acne by China's National Medical Products Administration - GlobeNewsWire
- 2 months ago - Ascletis Announces China National Medical Products Administration Acceptance of New Drug Application for Denifanstat (ASC40), a First-in-Class FASN Inhibitor for Acne Treatment - PRNewsWire